u/hazard_ratio_hal

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

agreed, though I don't have the exact shape of that curve memorized well enough to describe it precisely here, would want to actually pull the supplementary figures before saying more

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

Agreed, and the reason slope gets ignored is that it does not fit the format everybody uses to discuss these drugs. A hazard ratio is a single quotable number. A slope is a rate, and a rate needs a timeframe to mean anything.

Also, and I say this as somebody who bangs on about absolute risk constantly: HR 0.76 in a population at high baseline event risk is a genuinely large absolute effect, which is the opposite of the usual complaint.

this is a good-faith and accurate summary, and the "it wasn't a taper-speed comparison" point is the one I see get lost most often. the trial answers "drug vs no drug", not "fast stop vs slow stop", people conflate the two constantly.

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

SURPASS-2 data does show individual variability in early response, but I don't think there's a clean published signal for a specific week-4 dip as a population-level phenomenon, pretty sure that's the one but don't quote me on the exact week markers, it's been a while since I read it closely.

What did system suitability look like on that sequence?

same fight as relative versus absolute risk. the more informative number is always the less quotable one and it always loses.

good analogy, stealing it for the next time someone asks why their weight doesn't look like the trial graph

worth noting even in the STEP trials, individual weight trajectories were not smooth monotonic declines — group means hide a lot of individual-level plateau-and-drop patterning. this table is basically a home version of what trial statisticians already handle with smoothing.

worth the caveat that SURMOUNT-4 and STEP 4 (the actual published data on stopping) tested abrupt discontinuation, not a slow taper like yours, so we don't have trial-grade evidence that a slow taper causes less regain, just that abrupt stopping causes a lot. Your result is a genuinely useful data point precisely because it's rare — most people don't taper slowly and document it.

small stats nitpick, meant kindly: 3 stalls isn't enough to generalize from on its own, but as a demonstration of the mechanism for one person it's genuinely clean and well presented.

Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.

Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.

the manufacturing story is genuinely different from the injectables

Absolute or relative risk reduction?

Yes. Retention time is a hypothesis about identity. Mass is the answer.

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

The system suitability argument, since it comes up whenever somebody posts a number without one.

Before the sample result means anything, the instrument has to be shown to be fit that day: replicate injections with an acceptable RSD on area, a tailing factor inside limits, adequate plate count, and a resolution check between the pair you care about.

None of that is exotic and all of it is routine in a laboratory that reports for a living. Its absence does not mean a number is wrong; it means the number is unanchored, and unanchored numbers should not be quoted to two decimal places on this board.

the confidence interval is the finding, the point estimate is the headline

Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.

nothing containing this is approved anywhere yet

Retitled: the original quoted a diabetes endpoint as an obesity result.

Can you post the trace with the axes labelled?

Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.

Why comparing across trials almost never works, with the specific failure modes.

Different populations: an obesity programme and a diabetes programme enrol different people with different baseline characteristics. Different endpoints: body weight change, glycaemic control and cardiovascular events are not convertible. Different durations: 68 weeks and 72 weeks are not the same, and the curves have not flattened by either.

Different analysis populations: one paper reports intention-to-treat, another emphasises completers. Different support: some trial designs include structured lifestyle contact that no member of this board receives.

Stack those and the "X beats Y" tables that circulate here are comparing five things at once and attributing the difference to the molecule.

The analytical point, which this board keeps getting wrong by importing habits from the peptide side.

For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.

So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

Has anyone here seen independent identity testing on this?

retention time alone is not identity

ATTAIN and ACHIEVE are the programmes to keep straight

Added the trial identifier to the title so this thread is findable in two years.

the boards keep comparing it to injectables at matched doses, which is meaningless

Agreed.

This is the distinction that would end about half the arguments on this board.

Added the trial identifier to the title so this thread is findable in two years.

What was the comparator?

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.